Cadrenal Therapeutics starts formal strategic review
Cadrenal Therapeutics said it has initiated a formal strategic process to evaluate opportunities to maximize value of the company and its asset portfolio.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
Cadrenal Therapeutics starts strategic review
Cadrenal Therapeutics said its board authorized a formal strategic process to evaluate opportunities to maximize value of the company and its asset portfolio. Potential options include licensing or sale of individual assets, partnerships, portfolio transactions, business combinations or other strategic transactions.
Cadrenal Therapeutics Starts Strategic Review, Hires Advisor
Cadrenal Therapeutics has initiated a formal strategic process to evaluate various options including licensing, asset sales, partnerships, portfolio deals, or business combinations. The company has retained Tungsten Advisors as its exclusive strategic financial advisor.